Watch ELV. Know when insiders buy.
One email the day a filing lands. Free.
ELV
Elevance Health, Inc.
434.13
−6.05 −1.37%
USD · close Oct 21
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
46
WATCH · shorts 46
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $94.1BP/E 19.2DIV YIELD 1.58%FCF YIELD 6.68%REV TTM $201.1B +6.3%NET INCOME $5B −7.4%NET DEBT $20.8B52W 280.74 – 440.18SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $50.5B | +1.4% | 89.1% | $1.8B | $1.5B | −16.1% | 6.71 | $1.9B | $287M | $1.6B | Jul 15 |
| Q1 2026 · Mar 31 | $50.2B | +2.6% | 89.1% | $2.1B | $1.8B | −19.2% | 8.00 | $4.3B | $235M | $4.1B | Jul 15 |
| Q4 2025 · Dec 31 | $49.7B | +9.5% | 88.9% | $309M | $547M | +30.9% | 2.54 | $84M | $293M | −$209M | Feb 6 |
| Q3 2025 · Sep 30 | $50.7B | +12.4% | 89.4% | $1.3B | $1.2B | +17.0% | 5.32 | $1.1B | $360M | $775M | Apr 22 |
| Q2 2025 · Jun 30 | $49.8B | +13.4% | 89.4% | $2.4B | $1.7B | −24.2% | 7.72 | $2.1B | $267M | $1.8B | Jul 15 |
| Q1 2025 · Mar 31 | $48.9B | +14.8% | 89.8% | $3.2B | $2.2B | −2.8% | 9.61 | $1B | $196M | $821M | Jul 15 |
| Q4 2024 · Dec 31 | $45.4B | +6.6% | 86.8% | $673M | $418M | −51.2% | 1.87 | $706M | $322M | $384M | Feb 6 |
| Q3 2024 · Sep 30 | $45.1B | +5.3% | 88.7% | $1.4B | $1B | −21.2% | 4.36 | $2.7B | $332M | $2.3B | Apr 22 |
| Q2 2024 · Jun 30 | $43.9B | — | 89.0% | $2.8B | $2.3B | — | 9.85 | $447M | $323M | $124M | Feb 6 |
| Q1 2024 · Mar 31 | $42.6B | — | 91.0% | $3B | $2.2B | — | 9.59 | $2B | $279M | $1.7B | Feb 6 |
| Q4 2023 · Dec 31 | $42.6B | — | 88.7% | $1.3B | $856M | — | 3.66 | −$3B | $326M | −$3.3B | Feb 6 |
| Q3 2023 · Sep 30 | $42.8B | — | 89.2% | $1.8B | $1.3B | — | 5.45 | $2.6B | $319M | $2.3B | Feb 20 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $199.1B | 89.4% | $7.2B | $5.7B | 2.8% | 25.21 | $4.3B | $1.1B | $3.2B | $2.6B | $1.5B |
| FY2024 · to Dec 31 | $177B | 88.8% | $7.9B | $6B | 3.4% | 25.68 | $5.8B | $1.3B | $4.6B | $2.9B | $1.5B |
| FY2023 · to Dec 31 | $171.3B | 89.9% | $8.5B | $6B | 3.5% | 25.22 | $8.1B | $1.3B | $6.8B | $2.7B | $1.4B |
| FY2022 · to Dec 31 | $156.6B | 91.7% | $8.3B | $5.9B | 3.8% | 24.28 | $8.4B | $1.2B | $7.2B | $2.3B | $1.2B |
| FY2021 · to Dec 31 | $138.6B | 92.1% | $7.6B | $6.2B | 4.4% | 24.95 | $8.4B | $1.1B | $7.3B | $1.9B | $1.1B |
| FY2020 · to Dec 31 | $121.9B | 92.7% | $6.4B | $4.6B | 3.8% | 17.98 | $10.7B | $1B | $9.7B | $2.7B | $954M |
Every number comes from Elevance Health, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.